P505: SAFETY AND EFFICACY OF CASEIN KINASE 1Α AND CYCLIN DEPENDENT KINASE 7/9 INHIBITION IN PATIENTS WITH RELAPSED OR REFRACTORY AML: A PHASE 1, FIRST-IN-HUMAN STUDY OF BTX-A51
Main Authors: | B. J. Ball, G. Borthakur, A. Stein, K. W. Chan, D. Thai, E. M. Stein |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844908.44691.86 |
Similar Items
-
Identification of casein kinase 1, casein kinase 2, and cAMP-dependent protein kinase-like activities in Trypanosoma evansi
by: José Manuel Galán-Caridad, et al.
Published: (2004-12-01) -
Casein kinase 1α: biological mechanisms and theranostic potential
by: Shaojie Jiang, et al.
Published: (2018-05-01) -
Targeting Casein Kinase 1 (CK1) in Hematological Cancers
by: Pavlína Janovská, et al.
Published: (2020-11-01) -
Casein Kinase 1α as a Regulator of Wnt-Driven Cancer
by: Chen Shen, et al.
Published: (2020-08-01) -
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
by: Megías-Vericat JE, et al.
Published: (2019-06-01)